IL32 and Miyoshi myopathy: MM-EVs from wild-type high IL-32-expressing JJN3 myeloma cells were found to promote osteoclast differentiation, whereas pro-osteoclasts treated with EVs from IL-32-knockout (KO) JJN3 cells did not.